Stock analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.
View Our Latest Report on Minerva Neurosciences
Minerva Neurosciences Stock Performance
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Further Reading
- Five stocks we like better than Minerva Neurosciences
- Investing in Construction Stocks
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.